•Psoriasis is a chronic, immune-mediated disease whose key clinical symptoms include skin itching, pain, and scaling. Many psoriasis patients have reported decreases in their quality of life (QoL) and work productivity •Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A, clinical trials have shown significant efficacy in the treatment of moderate to severe -psoriasis (PsO) and psoriatic arthritis (PsA) •Little is known on secukinumab’s effectiveness on psoriasis in a real world setting
Disease characteristics, clinical and patient reported outcomes in psoriasis patients treated with secukinumab in a US real-world setting: Effectiveness Results from the Corrona Psoriasis Registry
Characterization of Disease Burden, Comorbidities and Therapy Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry
•Psoriasis (PsO) is an immune mediated chronic inflammatory disease with severe disease burden associated with several comorbidities and impact on quality of life. •The Corrona PsO registry, in collaboration with the National Psoriasis Foundation (NPF), was launched in April 2015 targeting to recruit approximately 200 sites with ~10,000 patients and an expected follow-up of at least 8 years and to study the comparative effectiveness, safety and treatment patterns of approved systemic therapies in a real world setting.
Comorbidity Burden and Characterization of Psoriasis (PsO) Patients with Concurrent Psoriatic Arthritis (PsA) in the Corrona Psoriasis Registry
•Psoriasis (PsO) is an immune mediated chronic inflammatory disease with severe disease burden associated with several comorbidities and impact on quality of life. Psoriatic arthritis (PsA) is a spondyloarthritic condition, which is present in up to 42% of individuals with psoriasis. •Studies have shown that patients with psoriasis, PsA or both generally have poorer quality of life outcomes, work productivity and functionality similar to other serious diseases such as heart disease and diabetes. •The objective of this study is to characterize the PsO patients with psoriatic arthritis (PsA) and examine association of outcomes with PsAin the Corrona Psoriasis Registry, a large prospective registry that was launched in collaboration with the National Psoriasis Foundation (NPF) to study the comparative effectiveness, safety of approved systemic PsO therapies and treatment patterns in a real world setting.